The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor

A Crilly, I.B. McInnes, H.A. Capell, R. Madhok

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Cytokine pathways are central to the perpetuation of synovial inflammation in rheumatoid arthritis (RA). Azathioprine (AZA) has disease modifying activity in RA. This study addressed the effect of AZA on serum IL-6 and soluble IL-2 receptor (sIL-2R) levels in RA. Over a 24 week period of therapy significant clinical improvement was observed. However, serum levels of both IL-6 and soluble IL-2R levels did not significantly change after AZA therapy. AZA therapy did not significantly alter the peripheral blood monocytes ability to produce IL-6 in vitro, either in the presence or absence of LPS. The mechanism by which AZA achieves clinical improvement in RA patients does not appear to be through IL-6 modulation or modification of synovial lymphocyte activation as assessed by serum sIL-2R levels.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalScandinavian Journal of Rheumatology
Volume23
Issue number2
DOIs
Publication statusPublished - 1994
Externally publishedYes

Keywords

  • Adult
  • Aged
  • Arthritis, Rheumatoid
  • Azathioprine
  • Cohort Studies
  • Female
  • Humans
  • Interleukin-6
  • Male
  • Middle Aged
  • Receptors, Interleukin-2
  • Solubility

Fingerprint Dive into the research topics of 'The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor'. Together they form a unique fingerprint.

Cite this